Alpha-9 Oncology
Andrew Groark currently serves as the Director of External Reporting & Technical Accounting at Alpha-9 Oncology since January 2025. Prior to this role, Andrew held positions at Fusion Pharmaceuticals from September 2020 to July 2024, including Associate Director and Senior Manager in SEC Reporting and Technical Accounting. Previous experience includes serving as Senior Manager of Accounting at KSQ Therapeutics, Inc. from May 2019 to September 2020 and various roles at EY from September 2013 to May 2019, including Audit Manager and Audit Senior. Andrew Groark earned a Bachelor of Business Administration in Accounting and a Bachelor of Science in Psychology from the Isenberg School of Management and the University of Massachusetts Amherst, respectively, completing studies from 2009 to 2013.
This person is not in any teams
Alpha-9 Oncology
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.